Autophagy Signaling

GW406108X is a selective inhibitor of Kif15 (Kinesin-12) and exhibits a significant inhibition of ULK1 kinase activity with a pIC50 of 6.37 (427 nM). This compound demonstrates potent autophagy inhibition, effectively blocking autophagic flux without impacting upstream signaling pathways such as mTORC1 and AMPK. GW406108X serves as a valuable tool in research focusing on autophagy regulation and related cellular processes.

ATG7-IN-3 is a highly effective inhibitor of ATG7, exhibiting an IC50 of 0.048 μM. This compound disrupts autophagy by preventing the formation of LC3B puncta, a critical process in the autophagic pathway. Research applications include investigations into glioma and colon cancer, making it a valuable tool for studying the role of autophagy in cancer biology.

20-Deoxyingenol is a diterpene compound identified from the roots of Euphorbia kansui, known for its role as an autophagy inducer. This compound promotes autophagy and lysosomal biogenesis by facilitating the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol is valuable for research into osteoarthritis (OA) and other conditions related to autophagy modulation.

Asperphenamate is an autophagy inducer derived from the fungal metabolite Aspergillus flatiipes, known for its anti-cancer properties. It demonstrates potent cytotoxic effects, with IC50 values of 92.3 μM in T47D cells, 96.5 μM in MDA-MB-231 cells, and 97.9 μM in HL-60 cells. This compound is valuable in cancer research for exploring autophagy modulation and evaluating therapeutic strategies targeting tumor cell survival.

mTOR inhibitor-8 is a potent inhibitor of the mechanistic target of rapamycin (mTOR), functioning through the interaction with FKBP12. This compound effectively suppresses mTOR activity and induces autophagy in A549 human lung cancer cells. It is a valuable tool for studying mTOR signaling pathways and the role of autophagy in cancer research.

C16 PEG2000 Ceramide is a polyethylene glycolylated ceramide that serves as an autophagy inducer. This compound promotes cellular autophagy processes, making it a valuable tool in cancer research. Additionally, C16 PEG2000 Ceramide can be utilized as a lipid carrier for targeted delivery of therapeutic agents in various experimental applications.

Autophagy Inducer 3 is an agent that promotes autophagy through the induction of lethal autophagic processes. It has been shown to effectively induce autophagic cell death in various cancer cell lines while sparing normal cells. The compound triggers the formation of characteristic autophagic vacuoles and LC3 puncta, along with the upregulation of key autophagy-related markers such as Beclin and members of the Atg protein family, making it valuable for research in cancer biology and autophagy modulation.

AUTEN-67 is an orally active autophagy enhancer that also functions as an inhibitor of MTMR14. This compound exhibits significant anti-aging and neuroprotective properties, effectively protecting neurons from stress-induced cell death. Additionally, AUTEN-67 has been shown to restore nesting behavior in mouse models of Alzheimer’s disease, making it a valuable tool for researchers studying neurodegenerative disorders and autophagy modulation.

2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a ligand for PD-L1, playing a crucial role in the development of AUTAC PD-L1 degrader-3. This compound is essential for facilitating targeted degradation of PD-L1, making it a valuable tool in cancer immunotherapy research and studies focusing on the modulation of immune checkpoints. Additionally, it can be utilized in the synthesis of AUTACs for advanced therapeutic applications.

Ac-Pro-Gly-Pro-OH acts as a CXCR2 agonist and is an endogenous degradation product of extracellular collagen. This compound demonstrates significant bactericidal activity through hydrogen peroxide generation and plays a role in inhibiting pulmonary inflammation while reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH promotes the secretion of IFN-γ and suppresses the levels of pro-inflammatory cytokines such as TNF-α and IL-6 in leukocytes. It is relevant for research applications in sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcers, notably influencing neutrophil behavior and tissue remodeling processes.

Elubrixin tosylate is a selective and reversible antagonist of the CXCR2 receptor, functioning as an IL-8 receptor antagonist. This compound effectively inhibits neutrophil CD11b upregulation with an IC50 of 260.7 nM and neutrophil shape change with an IC50 of 310.5 nM. Its biological activity positions Elubrixin tosylate as a valuable tool in research aimed at understanding and treating inflammatory diseases, including inflammatory bowel disease and airway inflammation.

Elubrixin is a potent and selective CXCR2 antagonist, functioning as a competitive and reversible inhibitor of the IL-8 receptor. It effectively impedes neutrophil CD11b upregulation with an IC50 of 260.7 nM and inhibits shape change with an IC50 of 310.5 nM. This compound is valuable in the study of inflammatory diseases, including inflammatory bowel disease and airway inflammation, facilitating insights into pathophysiological mechanisms and therapeutic interventions.

Elubrixin hydrochloride is a potent, selective CXCR2 antagonist that operates as a competitive, reversible inhibitor of the IL-8 receptor. It effectively inhibits neutrophil CD11b upregulation and shape change, with an IC50 of 260.7 nM and 310.5 nM, respectively. This compound is valuable for research applications related to inflammatory diseases, including inflammatory bowel disease and airway inflammation.

Burixafor hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4, effectively inhibiting the binding of CXCL12 to the CXCR4 receptor. This compound antagonizes CXCL12-induced recruitment of Gαᵢ and β-arrestin2, thereby obstructing the downstream Gαᵢ-mediated inhibition of cAMP signaling. Burixafor hydrobromide is utilized in research for mobilizing CD34+ hematopoietic stem/progenitor cells from the bone marrow to peripheral blood, making it valuable in studies related to autologous hematopoietic stem cell transplantation.

LRRK2-IN-17 is a potent inhibitor of Leucine-rich repeat kinase 2 (LRRK2), with IC50 values of 3.5 nM and 3.3 nM for wild-type and G2019S mutant variants, respectively. Additionally, it exhibits inhibitory activity against RET kinase with an IC50 of 59 nM. This compound is relevant for research applications related to cancer and Parkinson's disease, making it a valuable tool for investigating the role of LRRK2 in these conditions.

Leonurine hydrochloride is an alkaloid derived from Leonurus artemisia, acting primarily as an autophagy inhibitor. This compound exhibits notable anti-oxidative and anti-inflammatory properties, making it a valuable tool for research into cellular stress responses and inflammatory processes. It is particularly useful for studying the implications of autophagy modulation in various biological contexts, including neurodegenerative diseases and cancer.

9(R)-HODE is a monohydroxy fatty acid and an endogenous metabolite of linoleic acid, generated through the enzymatic actions of cyclooxygenase (COX) and lipoxygenase (LO). This compound is known to promote chemotaxis and elevate the expression of chemokine receptors CCR9 and CXCR4 in immune cells. Additionally, 9(R)-HODE effectively inhibits interleukin-6 (IL-6) release in primary human monocytes and suppresses CD3α- and CD28-induced proliferation in isolated human peripheral blood lymphocytes at a concentration of 25 μg/mL, making it a valuable tool for studying immune responses and inflammatory processes.

Clinopodiside A is a triterpenoid saponin that acts as an autophagy inducer. Isolated from the traditional Chinese medicinal herb Clinopodium polycephalum, it demonstrates significant potential in modulating cellular autophagy processes. This compound is useful for research applications exploring autophagy-related pathways and their implications in various diseases.

K1 peptide is a high-affinity ligand for GABAA receptor-associated protein (GABARAP). It plays a crucial role in mediating protein interactions involved in cellular processes such as autophagy and synaptic transmission. K1 peptide is valuable for research applications focused on GABARAP function and its implications in neurobiology and cellular signaling pathways.

Arylsulfonamide 64B is a potent inhibitor of hypoxia-inducible factor (HIF). This compound effectively suppresses hypoxia/HIF-mediated expression of key oncogenes such as c-Met and CXCR4, thereby demonstrating significant anti-tumor activity. Arylsulfonamide 64B is particularly relevant for research focused on uveal melanoma, as it has been shown to reduce primary tumor growth and metastasis in mouse models.

Ezurpimtrostat (hydrochloride) is a potent and selective PPT1 inhibitor with multiple biological activities. It disrupts lysosomal function, modulates autophagy, and induces apoptosis, making it a valuable tool in cancer research and immunology. This compound has demonstrated efficacy in reducing inflammatory markers such as IFN-α and CRP, as well as in lowering viral loads of SARS-CoV-2. Ezurpimtrostat is suitable for investigating conditions such as systemic lupus erythematosus, hepatocellular carcinoma, fibrosis, and other related disorders.

TSPO ligand-2 is a ligand of AUTAC1, specifically designed to target the MetAP2 enzyme. This compound features a p-fluorobenzylguanine (FBnG) moiety and a Fumagillol component, facilitating the selective degradation of MetAP2 within HeLa cells. It serves as a valuable tool for studying the regulation of protein homeostasis and the therapeutic potential of targeted protein degradation strategies in cellular models.

Corynoxine B is an alkaloid that acts as an autophagy inducer and an inhibitor of α-synuclein aggregation. It has demonstrated the ability to mitigate manganese-induced dysregulation of autophagy, thereby enhancing the clearance of α-synuclein in models of Parkinson's disease. This compound serves as a valuable tool for research into neurodegenerative disorders and the underlying mechanisms of autophagy regulation.

FBnG is a biochemical reagent that serves as a component of non-ribosomal peptide synthetase/polyketide synthase (NRPS/PKS), playing a critical role in the biosynthesis of fabrubactin (FBN). This compound is instrumental in the synthesis of AUTAC4, specifically within the context of the conjugate FBnG-(Cys-acetamide)-CH2-PEG3-CH2-CH2-CH2-NH2. It is valuable for researchers investigating peptide synthesis and complex molecular structures in drug development and biochemical studies.

VUF11207 is a potent agonist of the CXCR7 receptor, demonstrating a high affinity with a pKi of 8.1. This compound effectively induces the recruitment of β-arrestin2, with an pEC50 value of 8.8, and promotes the subsequent internalization of CXCR7, with an pEC50 of 7.9. VUF11207 is valuable for research applications focused on CXCR signaling pathways and β-arrestin-mediated processes.

Catenarin, an anthraquinone compound, serves as an inhibitor of CCR5 and CXCR4-mediated chemotaxis. It effectively reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), as well as calcium mobilization. Catenarin demonstrates anti-inflammatory properties and inhibits leukocyte migration, contributing to its potential in diabetes research. Additionally, it exhibits significant antibacterial activity against Gram-positive bacteria and has been shown to prevent type 1 diabetes in nonobese diabetic mice.

UCUF-965 is a positive allosteric modulator of the chemokine receptor CXCR4. This compound enhances CXCL12-induced β-arrestin recruitment and cAMP signaling, promoting lymphoblast migration and inducing calcium flux without binding to the orthosteric CXCL12 site. UCUF-965 also modulates microRNA levels in fibroblasts by reducing miR-15b and miR-29a, while increasing miR-146a. Its capabilities in enhancing angiogenesis and accelerating wound healing make UCUF-965 a valuable tool in research focused on diabetic wound healing impairment.

YU241279 is a selective inhibitor of CXCR5, targeting the CXCL13-mediated signaling pathways. It effectively inhibits Gαq-dependent calcium influx and Gαi2-dependent cAMP reduction in CXCR5-expressing cells, leading to reduced proliferation of lymphoma cells. In preclinical studies, YU241279 demonstrated a significant reduction in tumor burden within the peripheral blood and bone marrow of mice with lymphoma. This compound is suitable for research into angioimmunoblastic T-cell lymphoma and Burkitt B-cell lymphoma.

Xylitol is a polyol classified as a sugar alcohol, known for its inhibitory effects on cancer cell proliferation. It induces autophagy and promotes cell death in A549 lung cancer cells by activating the autophagy signaling pathway, as indicated by increased levels of LC3-II and Atg5-Atg12. Additionally, Xylitol reduces acetaldehyde production by Candida species, thereby mitigating their carcinogenic potential. In vivo studies demonstrate that Xylitol modifies gut microbiota in mice, potentially enhancing cholesterol accumulation, upregulating hepatic ChREBP, and inhibiting tumor growth in the B16F10 melanoma model.